Literature DB >> 18620539

Activated protein C via PAR1 receptor regulates survival of neurons under conditions of glutamate excitotoxicity.

L R Gorbacheva1, T P Storozhevykh, V G Pinelis, O N Davydova, S Ishiwata, S M Strukova.   

Abstract

The effect of an anticoagulant and cytoprotector blood serine proteinase--activated protein C (APC)--on survival of cultured hippocampal and cortical neurons under conditions of glutamate-induced excitotoxicity has been studied. Low concentrations of APC (0.01-10 nM) did not cause neuron death, but in the narrow range of low concentrations APC twofold and stronger decreased cell death caused by glutamate toxicity. High concentrations of APC (>50 nM) induced the death of hippocampal neurons similarly to the toxic action of glutamate. The neuroprotective effect of APC on the neurons was mediated by type 1 proteinase-activated receptor (PAR1), because the inactivation of the enzyme with phenylmethylsulfonyl fluoride or PAR1 blockade by a PAR1 peptide antagonist ((Tyr1)-TRAP-7) prevented the protective effect of APC. Moreover, APC inhibited the proapoptotic effect of 10 nM thrombin on the neurons. Geldanamycin, a specific inhibitor of heat shock protein Hsp90, completely abolished the antiapoptotic effect of 0.1 nM APC on glutamate-induced cytotoxicity in the hippocampal neurons. Thus, APC at low concentrations, activating PAR1, prevents the death of hippocampal and cortical neurons under conditions of glutamate excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18620539     DOI: 10.1134/s0006297908060138

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  7 in total

Review 1.  Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

Review 2.  Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.

Authors:  Arun Paul Amar; Abhay P Sagare; Zhen Zhao; Yaoming Wang; Amy R Nelson; John H Griffin; Berislav V Zlokovic
Journal:  Neuropharmacology       Date:  2017-09-18       Impact factor: 5.250

Review 3.  2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.

Authors:  John H Griffin; Laurent O Mosnier; José A Fernández; Berislav V Zlokovic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-06       Impact factor: 8.311

Review 4.  Activated protein C promotes neuroprotection: mechanisms and translation to the clinic.

Authors:  John H Griffin; José A Fernández; Patrick D Lyden; Berislav V Zlokovic
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

5.  Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Authors:  Zhihui Zhong; Hristelina Ilieva; Lee Hallagan; Robert Bell; Itender Singh; Nicole Paquette; Meenakshisundaram Thiyagarajan; Rashid Deane; Jose A Fernandez; Steven Lane; Anna B Zlokovic; Todd Liu; John H Griffin; Nienwen Chow; Francis J Castellino; Konstantin Stojanovic; Don W Cleveland; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

6.  Comparative analysis of cytosolic and mitochondrial ATP synthesis in embryonic and postnatal hippocampal neuronal cultures.

Authors:  Alexander M Surin; Serguei Khiroug; Lubov R Gorbacheva; Boris I Khodorov; Vsevolod G Pinelis; Leonard Khiroug
Journal:  Front Mol Neurosci       Date:  2013-01-10       Impact factor: 5.639

7.  New PAR1 Agonist Peptide Demonstrates Protective Action in a Mouse Model of Photothrombosis-Induced Brain Ischemia.

Authors:  Maksim Galkov; Ekaterina Kiseleva; Mikhail Gulyaev; Maria Sidorova; Liubov Gorbacheva
Journal:  Front Neurosci       Date:  2020-05-19       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.